Cargando…

Psoriasis Features in Patients with Inflammatory Bowel Disease

BACKGROUND: Psoriasis and inflammatory bowel diseases (IBD) share common pathways based on immune dysregulation with an important role of tumour necrosis factor-α and Th17 cells, as well as the genetic background. Several studies showed an increased prevalence of psoriasis in IBD patients. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Maddalena, Testa, Anna, Ferrillo, Maria, Villani, Alessia, Balato, Nicola, Megna, Matteo, Nardone, Olga Maria, Fabbrocini, Gabriella, Castiglione, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454185/
https://www.ncbi.nlm.nih.gov/pubmed/30976349
http://dx.doi.org/10.3889/oamjms.2019.161
_version_ 1783409524738097152
author Napolitano, Maddalena
Testa, Anna
Ferrillo, Maria
Villani, Alessia
Balato, Nicola
Megna, Matteo
Nardone, Olga Maria
Fabbrocini, Gabriella
Castiglione, Fabiana
author_facet Napolitano, Maddalena
Testa, Anna
Ferrillo, Maria
Villani, Alessia
Balato, Nicola
Megna, Matteo
Nardone, Olga Maria
Fabbrocini, Gabriella
Castiglione, Fabiana
author_sort Napolitano, Maddalena
collection PubMed
description BACKGROUND: Psoriasis and inflammatory bowel diseases (IBD) share common pathways based on immune dysregulation with an important role of tumour necrosis factor-α and Th17 cells, as well as the genetic background. Several studies showed an increased prevalence of psoriasis in IBD patients. However, data regarding psoriasis features in IBD patients are still lacking. AIM: We aimed to conduct an observational study to assess psoriasis clinical features and its severity in a group of patients with IBD. METHODS: Dermatological assessment was performed consecutively in 200 IBD patients (123 with CD and 77 with UC) attending the IBD Care Centre of Gastroenterology at the University of Naples Federico II from 2015 to 2016. RESULTS: A group of 32 from 200 IBD patients (16%) had a familiar history positive for psoriasis, whereas, medical history and dermatologic examination revealed that 18 (9%) IBD patients were affected by psoriasis: 11 out of these 18 subjects (61.2%) had CD, and 7 had UC (38.2%); no significant differences were found between CD and UC groups. Concerning psoriasis severity, the mean psoriasis area severity index score was 3.7. CONCLUSION: This one-year retrospective study showed that psoriasis and IBD both require the use of immunosuppressive drugs so; we can count on a better treatment outcome for both diseases.
format Online
Article
Text
id pubmed-6454185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-64541852019-04-11 Psoriasis Features in Patients with Inflammatory Bowel Disease Napolitano, Maddalena Testa, Anna Ferrillo, Maria Villani, Alessia Balato, Nicola Megna, Matteo Nardone, Olga Maria Fabbrocini, Gabriella Castiglione, Fabiana Open Access Maced J Med Sci Clinical Science BACKGROUND: Psoriasis and inflammatory bowel diseases (IBD) share common pathways based on immune dysregulation with an important role of tumour necrosis factor-α and Th17 cells, as well as the genetic background. Several studies showed an increased prevalence of psoriasis in IBD patients. However, data regarding psoriasis features in IBD patients are still lacking. AIM: We aimed to conduct an observational study to assess psoriasis clinical features and its severity in a group of patients with IBD. METHODS: Dermatological assessment was performed consecutively in 200 IBD patients (123 with CD and 77 with UC) attending the IBD Care Centre of Gastroenterology at the University of Naples Federico II from 2015 to 2016. RESULTS: A group of 32 from 200 IBD patients (16%) had a familiar history positive for psoriasis, whereas, medical history and dermatologic examination revealed that 18 (9%) IBD patients were affected by psoriasis: 11 out of these 18 subjects (61.2%) had CD, and 7 had UC (38.2%); no significant differences were found between CD and UC groups. Concerning psoriasis severity, the mean psoriasis area severity index score was 3.7. CONCLUSION: This one-year retrospective study showed that psoriasis and IBD both require the use of immunosuppressive drugs so; we can count on a better treatment outcome for both diseases. Republic of Macedonia 2019-03-28 /pmc/articles/PMC6454185/ /pubmed/30976349 http://dx.doi.org/10.3889/oamjms.2019.161 Text en Copyright: © 2019 Maddalena Napolitano, Anna Testa, Maria Ferrillo, Alessia Villani, Nicola Balato, Matteo Megna, Olga Maria Nardone, Gabriella Fabbrocini, Fabiana Castiglione http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Clinical Science
Napolitano, Maddalena
Testa, Anna
Ferrillo, Maria
Villani, Alessia
Balato, Nicola
Megna, Matteo
Nardone, Olga Maria
Fabbrocini, Gabriella
Castiglione, Fabiana
Psoriasis Features in Patients with Inflammatory Bowel Disease
title Psoriasis Features in Patients with Inflammatory Bowel Disease
title_full Psoriasis Features in Patients with Inflammatory Bowel Disease
title_fullStr Psoriasis Features in Patients with Inflammatory Bowel Disease
title_full_unstemmed Psoriasis Features in Patients with Inflammatory Bowel Disease
title_short Psoriasis Features in Patients with Inflammatory Bowel Disease
title_sort psoriasis features in patients with inflammatory bowel disease
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454185/
https://www.ncbi.nlm.nih.gov/pubmed/30976349
http://dx.doi.org/10.3889/oamjms.2019.161
work_keys_str_mv AT napolitanomaddalena psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT testaanna psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT ferrillomaria psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT villanialessia psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT balatonicola psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT megnamatteo psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT nardoneolgamaria psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT fabbrocinigabriella psoriasisfeaturesinpatientswithinflammatoryboweldisease
AT castiglionefabiana psoriasisfeaturesinpatientswithinflammatoryboweldisease